Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q1 2025 value amounting to $72.1 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 4708.11% to $72.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $72.1 million, marking a year-over-year increase of 4708.11%. This contributed to the annual value of $61.0 million for FY2024, which is 2698.56% up from last year.
  • According to the latest figures from Q1 2025, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) is $72.1 million, which was up 4708.11% from $61.0 million recorded in Q4 2024.
  • In the past 5 years, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $72.1 million in Q1 2025 and a low of $46.6 million during Q1 2022
  • For the 4-year period, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $50.9 million, with its median value being $47.5 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first rose by 0.57% in 2023, then skyrocketed by 4708.11% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $46.6 million in 2022, then increased by 3.16% to $48.0 million in 2023, then grew by 26.99% to $61.0 million in 2024, then grew by 18.27% to $72.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $72.1 million for Q1 2025, versus $61.0 million for Q4 2024 and $49.0 million for Q1 2024.